Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

Original reporting
Published Nov 6, 2026, 5:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SIBullishMed
01

Why it matters

The key tradable items are the FY2026 net revenue guidance raise, Q3 revenue and gross margin strength, and early commercialization progress for next-generation implants, all framed against orthopedic seasonality and CMS reimbursement developments.

02

Market read

A company-specific earnings call with a concrete guidance raise and multiple operating metrics can drive near-term positioning and expectations for 2026 demand and margins.

03

What to watch

The transcript notes more pronounced seasonality among core surgeons and incremental cost initiatives expected to contribute beginning in 2027, which could affect margin trajectory beyond 2026.

Relevance 8/10Novelty 7/10Timing: after-hours earnings call transcript, guidance update for FY2026

Background

The company discusses Q3 performance, surgeon adoption and utilization, and commercialization of InSet Go and N-22 products, alongside favorable CMS final rulings.

Company-level read

Ticker impact

$SIBullishMedium confidence
Context

Shoulder Innovations raised full-year 2026 net revenue guidance to $68M-$70M and reported Q3 revenue up 38% YoY with 78.5% gross margin.

Expected impact

Likely upward bias as traders price in higher 2026 revenue growth and margin durability, while monitoring adoption and CMS-related demand.

Evidence & confidence

The article contains a fresh guidance update with specific ranges and multiple operating datapoints (revenue, gross margin, implant volume) plus product commercialization milestones and favorable CMS rulings.

Market effects

Reinforces demand and reimbursement tailwinds for shoulder arthroplasty device makers following favorable CMS rulings.

Primarily US-focused commercial execution and surgeon adoption dynamics.

Limited direct global impact; US reimbursement and orthopedic procedure volumes are the main driver.

Counterpoint

Raised guidance may already reflect expected seasonality normalization, so upside could be capped if surgeon funnel conversion or implant utilization slows in Q4.

Key entities

  • Shoulder Innovations

    Orthopedic implant company reporting Q3 results and raising FY2026 net revenue guidance; launching InSet Go and N-22 products.

  • CMS (Centers for Medicare & Medicaid Services)

    CMS final rulings related to shoulder arthroplasty referenced as favorable for the company’s market.

  • InSet Go

    Next-generation glenoid implant launched with reduced surgical steps; surgeons report positive response.

  • N-22 humeral head

    FDA-cleared N-22 humeral head launched to extend the N-22 line for metal hypersensitivity into anatomic procedures.

Related articles

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.